NASDAQ: ATAIAtai Life Sciences Nv Stock
$1.77+0.00 (+0%)
Updated May 26, 2023
ATAI Price
$1.77
Fair Value Price
N/A
Market Cap
$293.84M
52 Week Low
$1.14
52 Week High
$4.96
P/E
-1.84x
P/B
1.24x
P/S
1,048.27x
PEG
N/A
Dividend Yield
N/A
Revenue
$269.00k
Earnings
-$148.65M
Gross Margin
100%
Operating Margin
-52,667.66%
Profit Margin
-55,260.6%
Debt to Equity
0.17
Operating Cash Flow
-$102M
Beta
1.37
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ATAI Overview
Atai Life Sciences N.V. is a clinical-stage biopharmaceutical company developing various therapeutic candidates that focus on various mental health disorders including depression, substance use disorder, and anxiety. The company's pipeline includes PCN-101, RL-007, DMX-1002, GRX-917, NN-101, VLS-01, EMP-01, RLS-01, DMX-1001, and others. Formerly known as Adripa Holding B.V., Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ATAI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ATAI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ATAI is good value based on its book value relative to its share price (1.24x), compared to the US Biotechnology industry average (5.18x)
P/B vs Industry Valuation
ATAI is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ATAI due diligence checks available for Premium users.
Be the first to know about important ATAI news, forecast changes, insider trades & much more!
ATAI News
Valuation
ATAI fair value
Fair Value of ATAI stock based on Discounted Cash Flow (DCF)
Price
$1.77
Fair Value
$2.39
Undervalued by
25.95%
ATAI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ATAI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.84x
Industry
11.86x
Market
54.23x
ATAI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.24x
Industry
5.18x
ATAI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ATAI's financial health
Profit margin
Revenue
$37.0k
Net Income
-$33.1M
Profit Margin
-89,554.1%
ATAI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ATAI's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$280.7M
Liabilities
$40.1M
Debt to equity
0.17
ATAI's short-term assets ($267.93M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ATAI's short-term assets ($267.93M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ATAI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$21.1M
Investing
$16.0M
Financing
$206.0k
ATAI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ATAI vs Biotech Stocks
Atai Life Sciences Nv Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.